shutterstock_1201562074_designer491

designer491 / Shutterstock.com

29 April 2019Americas

LSPN 19: Humira litigation may prompt more antitrust scrutiny

The six antitrust class-action lawsuits that have been brought against AbbVie could result in more scrutiny of settlement agreements between the innovator and the biosimilar manufacturer, with potential antitrust complications.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

UPC orders 17-country ban on EOFlow's pumps in Insulet feud

US warns of rising counterfeit drug threat from India and China

Judge denies Pfizer and BioNTech bid to see off COVID-19 vaccine suit

Biotech and healthcare expert returns to Latham & Watkins

AstraZeneca to appeal invalidated diabetes patent in generics dispute

Why US patent reform is ‘essential’ for US economic prosperity and security

Medical company sees $452m trade secrets award cut by 87%

Fed Circ: Generic doesn’t infringe Metacel MS drug